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Abstract. 
 
In humans, defects in peroxisome biogenesis 
are the cause of lethal diseases typiﬁed by Zellweger 
syndrome. Here, we show that inactivating mutations in 
human 
 
PEX3
 
 cause Zellweger syndrome, abrogate per-
oxisome membrane synthesis, and result in reduced 
abundance of peroxisomal membrane proteins (PMPs) 
and/or mislocalization of PMPs to the mitochondria. 
Previous studies have suggested that PEX3 may trafﬁc 
through the ER en route to the peroxisome, that the 
COPI inhibitor, brefeldin A, leads to accumulation of 
PEX3 in the ER, and that PEX3 overexpression alters 
the morphology of the ER. However, we were unable 
to detect PEX3 in the ER at early times after expres-
sion. Furthermore, we ﬁnd that inhibition of COPI 
function by brefeldin A has no effect on trafﬁcking of 
PEX3 to peroxisomes and does not inhibit 
 
PEX3
 
-medi-
ated peroxisome biogenesis. We also ﬁnd that inhibition 
of COPII-dependent membrane trafﬁc by a dominant 
negative SAR1 mutant fails to block PEX3 transport to 
peroxisomes and 
 
PEX3
 
-mediated peroxisome synthe-
sis. Based on these results, we propose that PEX3 tar-
geting to peroxisomes and 
 
PEX3
 
-mediated peroxisome 
membrane synthesis may occur independently of 
COPI- and COPII-dependent membrane trafﬁc.
Key words: Zellweger syndrome • membrane biogen-
esis • protein import • vesicle trafﬁc • peroxisome bio-
genesis disorders
 
Introduction
 
Eukaryotic cells contain numerous subcellular organelles.
The division of cellular metabolism among these special-
ized compartments allows for the concentration of related
activities, segregation of competing functions, and the for-
mation of unique microenvironments. However, the as-
sembly and maintenance of these organelles is complex
and involves several interrelated processes. These include
the recognition of proteins destined for particular organelles,
transport of these proteins to and into the organelle lu-
men, and the biogenesis of the organelle membrane (Schatz
and Dobberstein, 1996). Peroxisomes are present in virtu-
ally all eukaryotes and their assembly is thought to involve
these same general processes. However, our knowledge of
peroxisome biogenesis, particularly those aspects that re-
late to formation of peroxisome membranes, is far from
complete.
Peroxisomes lack nucleic acids and must therefore im-
port all of their protein content (Lazarow and Fujiki,
1985). Peroxisomes have a single membrane, are 
 
z
 
0.1–1
 
m
 
m in diameter, and have a dense proteinaceous matrix.
The metabolic roles of peroxisomes can vary considerably,
but human peroxisomes contribute primarily to the 
 
a
 
-oxi-
dation and 
 
b
 
-oxidation of fatty acids, as well as the synthe-
sis of ether-linked phospholipids and isoprene compounds
(Wanders and Tager, 1998). The peroxisomal enzymes in-
volved in these processes are encoded by nuclear genes,
are synthesized in the cytoplasm, and imported in a post-
translational fashion (Lazarow and Fujiki, 1985). Two dif-
ferent targeting signals have been identified for matrix
enzymes, the COOH-terminally located PTS1, which di-
rects most proteins to peroxisomes, and the NH
 
2
 
-terminal
PTS2, which directs only a small number of proteins into
the peroxisome (Subramani, 1993).
Genetically determined, lethal diseases are caused by
defects in any of several different peroxisomal enzymes,
underscoring the importance of peroxisomal contribu-
tions to metabolism (Wanders and Tager, 1998). However,
Zellweger syndrome, neonatal adrenoleukodystrophy, in-
fantile Refsum disease, and rhizomelic chondrodysplasia
punctata represent a different set of lethal peroxisomal
disorders. Rather than lacking a single peroxisomal en-
zyme, these patients lack virtually all peroxisomal meta-
bolic functions, a phenotype that results from defects in
the import of one or more classes of peroxisomal matrix
proteins (Lazarow and Moser, 1995). Theoretically, the
peroxisomal matrix protein import defects observed in
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these peroxisome biogenesis disorder (PBD)
 
1
 
 patients
could be caused by mutations in either of two different
types of genes, those that encode peroxisomal matrix pro-
tein import factors (Chang et al., 1999a), and those that
encode factors necessary for peroxisome membrane bio-
genesis (Honsho et al., 1998; Matsuzono et al., 1999; South
and Gould, 1999; Sacksteder et al., 2000).
Cellular studies have revealed that most PBD patients
display an isolated defect in peroxisomal matrix protein
import (Santos et al., 1988a,b; Chang et al., 1999a). Cells
from these patients contain nearly a hundred peroxisomes
and import peroxisomal membrane proteins (PMPs) nor-
mally, even though they display mild to severe defects in
peroxisomal matrix protein import. This phenotype is ge-
netically heterogeneous and can be caused by loss of any
of at least eight different peroxins (proteins required for
peroxisome biogenesis). These include the receptors for
newly synthesized peroxisomal matrix proteins, PEX5 and
PEX7, as well as other peroxins that are required for per-
oxisomal matrix protein import (PEX1, PEX2, PEX6,
PEX10, PEX12, and PEX13; Chang et al., 1999a).
A different phenotype recently has been described for a
few rare Zellweger syndrome patients. These patients lack
detectable peroxisomes altogether and are unable to im-
port integral peroxisomal membranes into recognizable
peroxisome-like structures (Honsho et al., 1998; Matsu-
zono et al., 1999; South and Gould, 1999; Sacksteder et al.,
2000). This phenotype could result from either a defect in
PMP import, which is distinct from peroxisomal matrix
protein import, or a defect in peroxisome membrane syn-
thesis. In humans, this phenotype can be caused by muta-
tions in 
 
PEX16
 
 (Honsho et al., 1998; South and Gould,
1999) or 
 
PEX19
 
 (Matsuzono et al., 1999; Sacksteder et al.,
2000), and reexpression of either gene results in the refor-
mation of peroxisomes in the mutant cells. Although these
results demonstrate that peroxisome synthesis can occur in
the absence of preexisting peroxisomes, the mechanism
for this mode of peroxisome membrane synthesis remains
obscure. One hypothesis is that peroxisomes may arise
from some other endomembrane of the cell (South and
Gould, 1999), perhaps the ER (Titorenko and Rachubin-
ski, 1998a), and may involve COPI-dependent processes
(Solomons et al., 1997; Passreiter et al., 1998; Mullen et al.,
1999). Here, we show that two Zellweger syndrome pa-
tients who lack detectable peroxisomes are each homozy-
gous for inactivating mutations in 
 
PEX3
 
, which itself en-
codes a PMP (Höhfeld et al., 1991; Kammerer et al., 1998;
Soukupova et al., 1999). Studies of PEX3 import fail to
demonstrate a role for the ER, COPI, or COPII in PMP
targeting, and studies of 
 
PEX3
 
-mediated peroxisome bio-
genesis suggest that it can proceed independently of both
COPI and COPII.
 
Materials and Methods
 
Tissue Culture, Cell Lines, Antibodies, and Reagents
 
Skin fibroblasts were obtained from Ann and Hugo Moser (The Kennedy
Krieger Institute, Baltimore, MD), the Coriell Cell Repository (Camden,
NJ), and Manuel Santos (The Catholic University of Chile, Santiago,
Chile). HepG2 cells were obtained from Michael Schrader (The Johns
Hopkins University, Baltimore, MD). All cell lines were cultured in high
glucose DME supplemented with penicillin, streptomycin, and 10% FCS.
The mutations identified in the PBD patient cell lines used for the PEX13
immunoblot have been described elsewhere (South and Gould, 1999).
Antibodies to catalase were obtained commercially (The Binding Site,
Inc.). Antibodies to PMP70 were generated to a COOH-terminal 18
amino acid peptide conjugated to maleimide-activated keyhole limpet
hemocyanin (Pierce Chemical Co.) and injected into either sheep or
guinea pigs. Antibodies to PEX13 were generated to a COOH-terminal
13 amino acid peptide conjugated to maleimide-activated keyhole limpet
hemocyanin and injected into rabbits. Antibodies to PEX3 and PEX14
were generated by expressing a portion of each protein missing its puta-
 
tive NH
 
2
 
-terminal transmembrane domain (amino acids 147–373 and
127–377, respectively) in fusion with maltose-binding protein. The result-
ing fusion proteins were purified by affinity chromatography on amylose
resin (New England Biolabs, Inc.) and injected into rabbits. Antibodies to
PEX11
 
b
 
 were generated by fusing glutathione S-transferase to amino ac-
ids 1–227 and expressing the fusion protein in bacteria and isolating the in-
clusion body. The inclusion body was washed with 1% NP-40, then with
2 M urea, and finally with PBS. The resulting protein lysate was analyzed by
 
SDS-PAGE and was found to be 
 
z
 
80% PEX11
 
b
 
 fusion protein, and was
then injected into rabbits. Polyclonal sera was collected and was either
used directly or was purified by affinity chromatography using either puri-
fied fusion protein or peptide conjugated to cyanogen bromide sepharose
beads (Sigma Chemical Co.). mAbs to the myc epitope were obtained
from the tissue culture supernatant of the hybridoma 1-9E10 (Evan et al.,
1985). Polyclonal antibodies to the myc and HA epitopes and mAbs to
the vsvg epitope were obtained from commercial sources. Fluorescently
labeled secondary antibodies and HRP-labeled anti-rabbit secondary
antibodies were also obtained from commercial sources (Jackson Immu-
noResearch Laboratories). MitoTracker and FITC-C
 
5
 
-ceramide were in-
corporated into living cells according to the manufacturer’s instructions
(Molecular Probes).
 
Transfection, Microinjection, and Immunofluorescence
 
All cell lines were actively growing before transfection or microinjection.
Transfections were performed by growing cells to near confluency, har-
vesting the cells by trypsinization, and electroporating them as described
(Chang et al., 1997). Microinjections were performed with DNA at a con-
centration of 10 
 
m
 
g/ml in reverse PBS (4 mM NaHPO
 
4
 
, 1 mM KH
 
2
 
PO
 
4
 
,
140 mM KCl, pH 7.3). DNAs were injected into the nucleus of cells at a
pressure of 100 mm Hg for 0.4 s. Cells were cultured on glass coverslips
and processed for indirect immunofluorescence as described (South and
Gould, 1999) with the exception that digitonin permeabilization was nec-
essary for visualization of PEX11
 
b
 
 (Schrader et al., 1998).
 
Protein Preps, Western Blots, and Fractionations
 
Total cellular proteins were extracted from cultured fibroblasts as de-
scribed (Dodt and Gould, 1996). For subcellular fractionation experi-
ments, postnuclear supernatants were prepared from HepG2 cells by ho-
mogenization, followed by centrifugation to remove nuclei and unbroken
cells. The clarified supernatant was separated by density gradient centrifu-
gation using Nycodenz (Nycomed Pharma) as described (Dodt et al.,
1995). Equal amounts of each fraction were assayed for catalase, succinate
dehydrogenase (SDH), and NADPH-cytochrome reductase (NCR) to
identify peroxisomal, mitochondrial, and microsomal fractions, respec-
tively. Equal amounts of each fraction were also separated by SDS-PAGE
and assayed for PEX3 levels by Western blot as described (Crane et al.,
1994).
 
Clonings and Mutation Detection
 
pcDNA3-
 
PEX3
 
 was created by PCR amplification of a human liver
cDNA library using the 
 
PEX3
 
-specific oligonucleotides 5
 
9
 
-CCAGGTAC-
CATGCTGAGGTCTGTATGGAATTTTC-3
 
9
 
 and 5
 
9
 
-CCAAGTCGA-
CTCATTTCTCCAGTTGCTGGAGGG-3
 
9
 
. The resulting PCR product
was digested with Asp718 and SalI and cloned between the Asp718 and
XhoI sites of pcDNA3 (Invitrogen). pcDNA3-
 
PEX3myc
 
 was created by
PCR amplification of a human liver cDNA library using the PEX3-spe-
cific oligonucleotides 5
 
9
 
-CCAGGTACCATGCTGAGGTCTGTATG-
GAATTTTC-3
 
9
 
 at the 5
 
9
 
 end, and 5
 
9
 
-CCAAAGATCTTTTCTCCAGT-
 
1
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 BFA, brefeldin A; GALT, 
 
b
 
-1,4-galac-
tosyltransferase; ORF, open reading frame; PBD, peroxisome biogenesis
disorder; PMP, peroxisomal membrane protein; RT, reverse transcriptase;
WT, wild-type. 
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TGCTGGAGGG-3
 
9
 
 at the 3
 
9
 
 end, which replaces the stop codon with a
BglII site. The resulting PCR product was digested with Asp718 and BglII
and cloned between the Asp718 and BamHI sites of a modified pcDNA3
vector encoding the ten–amino acid c-myc epitope. The resulting plasmid
contained the full-length cDNA sequence of 
 
PEX3 
 
fused at its COOH
terminus to the myc epitope, followed immediately by a stop codon. The
plasmids designed to express PEX12myc, PEX13myc, ALDPmyc, and
PMP34myc all consist of the full-length human cDNA cloned into the
same modified pcDNA-myc–containing vector. The sequence of mouse
 
SAR1a
 
 was used to identify human 
 
SAR1
 
 through BLAST searches of the
human database of expressed sequence tags. Clones encoding the human
 
SAR1
 
 were obtained from Genome Systems Inc., and were sequenced in
their entirety. Human 
 
SAR1
 
 was first amplified with the oligonucleo-
tides 5
 
9
 
-CCCGGTACCATGTCTTTCATCTTTGAGTGGATC-3
 
9
 
 and
5
 
9
 
-CACCGGATCCGTCAATATACTGGGAGAGCCAGC-3
 
9
 
, and then
cloned into a modified pcDNA3 vector encoding the six–amino acid vsvg
epitope such that the resulting plasmid, pcDNA3-
 
SAR1
 
, contained the
full-length sequence of human 
 
SAR1
 
 with its COOH terminus fused to the
vsvg epitope, immediately, followed by a stop codon. pcDNA3-
 
SAR1/
T39N/vsvg
 
 was created by PCR site-directed mutagenesis using the oligo-
nucleotides 5
 
9
 
-CCCGGTACCATGTCTTTCATCTTTGAGTGGATC-
3
 
9
 
 and 5
 
9
 
-GGAACATGTTGGCCCAATCTGTCATCTTTGAGCAT-
GTGAAGAAGAGTAATTTTGCC-3
 
9
 
, which creates a PCR fragment
identical to the wild-type (WT) human 
 
SAR1
 
 sequence, with the excep-
tion of an ACC to AAT codon change that converts the threonine at posi-
tion 39 in the amino acid sequence to an asparagine. This PCR fragment
was cut with Asp718 and AflIII and used to replace its complementary se-
quence in pcDNA3
 
-SAR1
 
, also cut with Asp718 and AflIII. pcDNA3-
 
SAR1/T39N/vsvg
 
 was sequenced to determine that only the T39N
mutation was introduced during the amplification process. pcDNA3-
 
GALT3xHA
 
 was created by PCR amplification using the oligonucleotides
5
 
9
 
-CCCGGTACCATGAGGCTTCGGGAGCCGCTCC-3
 
9
 
 and 5
 
9
 
-CCC-
AGATCTCCCTCCGGTCCGGAGCTCCCCG-3
 
9
 
, and pECFP-Golgi
vector (CLONTECH Laboratories, Inc.) as template. The resulting PCR
product was digested with Asp718 and BglII and cloned into a modified
pcDNA3 vector encoding three copies of the nine–amino acid human in-
fluenza virus hemagglutinin, HA1 epitope, such that the resulting plasmid
contained the targeting sequence from human 
 
b
 
-1,4-galactosyltransferase
(GALT) fused at the COOH terminus to three copies of the HA epitope
immediately followed by a stop codon. All PCR-generated clones were se-
quenced in their entirety to ensure that no mutations were introduced
during the amplification process.
Mutation detection was performed initially by reverse transcriptase
(RT)-PCR. RNA was extracted from normal human fibroblasts, PBD400
fibroblasts, and PBD401 fibroblasts, and were converted to 
 
PEX3 
 
cDNA
as follows. Approximately 1 
 
m
 
g of total RNA from control and patient
samples was used as template in a cDNA synthesis reaction using the
 
PEX3
 
-specific oligonucleotide 5
 
9
 
-CCAAGCGGCCGCATTTTGATAA-
CAAACTGTTACTC-3
 
9
 
, which is located in the 3
 
9 
 
untranslated region,
using Superscript reverse transcriptase (Life Sciences Inc.). 3 
 
m
 
l of the
cDNA synthesis reaction products were used as templates in PCRs using
the 
 
PEX3
 
-specific oligonucleotide 5
 
9
 
-CCAAGTCGACTCATTTCTC-
CAGTTGCTGGAGGG-3
 
9
 
, which is at the 3
 
9
 
 end of the 
 
PEX3
 
 open
reading frame (ORF), but is upstream of the oligonucleotide used in the
cDNA synthesis reaction, and the oligonucleotide 5
 
9
 
-CCAGGTACCAT-
GCTGAGGTCTGTATGGAATTTTC-3
 
9
 
, which is at the 5
 
9
 
 end of the
 
PEX3
 
 ORF. The resulting PCR products were directly sequenced. The
control fragment exactly matched the
 
 PEX3
 
 cDNA sequence. In contrast,
the 
 
PEX3
 
 fragment from PBD400 had a single nucleotide insertion after
nt 542 of the ORF, c.542insT, which shifts the reading frame and termi-
nates translation after ten out-of-frame codons. The
 
 PEX3
 
 fragment from
PBD401 had a nonsense mutation at codon 53, R53ter. These mutations
were confirmed at the genomic level by extracting total human genomic
DNA from control, PBD400, and PBD401 fibroblasts. Control genomic
DNA and PBD400 genomic DNA was amplified using oligonucleotides
complementary to the sequence surrounding exon 7, which is where the
nucleotide insertion found in PBD400 cDNA should reside (5
 
9
 
-ACAAT-
TCTTGCTCCCCCAGATGTCCAAC-3
 
9
 
 and 5
 
9
 
-CAAATCACCGTTT-
GTCAAGTCACTGG-3
 
9
 
). Control genomic DNA and PBD401 genomic
DNA was amplified using oligonucleotides complementary to intronic se-
quence surrounding exon 2, which is where the nonsense mutation found
in PBD401 cDNA should reside (5
 
9
 
-TTCCCTTCCTCAAACCTGGTCC-
3
 
9
 
 and 5
 
9
 
-TTGTTCACTTCCTGCTTCCCCAG-3
 
9
 
). The PCR products
were sequenced directly.
The plasmids pcDNA3-
 
PEX3
 
/c.542ins
 
T
 
 and pcDNA3-
 
PEX3
 
/R53ter
were created by cloning the RT-PCR products generated during the muta-
tion detection process described above into the pCR2.1 vector (Invi-
trogen). The resulting clone was sequenced in its entirety to ensure that
no other mutations were introduced during the amplification process and
to ensure correct orientation of the inserts. The inserts were released from
pCR2.1 by digestion with Asp718 and NotI and cloned into the Asp718
and NotI sites of pcDNA3.
 
Results
 
PBD400 and PBD401 Cells Are Defective in 
Peroxisome Membrane Synthesis
 
Complementation group 12 of the PBDs was identified
previously by cell fusion complementation studies (Poulos
et al., 1995). We examined the peroxisomes in two cell
lines from CG12, PBD400, and PBD401. Immunofluores-
cent staining demonstrated that these cells failed to com-
partmentalize the peroxisomal matrix protein marker cat-
alase (Fig. 1, A–C), the common phenotype of cells from
Zellweger Syndrome patients (Santos et al., 1988a,b; Chang
et al., 1999a). However, these cells also lacked detectable
PMP-containing peroxisome membranes, shown here by
the absence of staining for the membrane marker protein,
PMP70 (Fig. 1, D–F). We tested whether peroxisomes
might be detected using antibodies to other integral PMPs
by staining WT, PBD400, and PBD401 cells with antibod-
ies specific for PEX13 (Gould et al., 1996; Bjorkman et al.,
1998) and PEX11
 
b
 
 (Schrader et al., 1998). Although
PEX13 and PEX11
 
b
 
 are readily detected in peroxisomes
of WT cells, they are not visible in PBD400 or PBD401
cells (Fig. 1, G–L). This phenotype is unusual for PBD cell
lines, as null mutations in most 
 
PEX
 
 genes affect only ma-
trix protein import, but this has been observed previously
in Zellweger Syndrome patient cells mutated for 
 
PEX16
 
(Honsho et al., 1998; South and Gould, 1999) or 
 
PEX19
 
(Matsuzono et al., 1999; Sacksteder et al., 2000).
The lack of punctate staining for PMP70, PEX13, and
PEX11
 
b
 
 in PBD400 and PBD401 cells was not accompa-
nied by any detectable staining for these PMPs in the cyto-
plasm or any other cellular compartment, indicating that
the abundance of these PMPs may be reduced in PBD400
and PBD401 cells. We previously established that levels of
PMP70 and another PMP, P70R, fall below the limit of de-
tection in 
 
PEX16
 
-deficient cells (South and Gould, 1999).
Furthermore, the low levels of PMP70 reported in 
 
PEX19
 
-
deficient mammalian cells appear to be caused by rapid
proteolysis of this integral PMP (Kinoshita et al., 1998;
Matsuzono et al., 1999). Here, we examined the levels of
another integral PMP, PEX13, in PBD400 cells, as well as
in human fibroblasts with inactivating mutations in various
 
PEX
 
 genes (Fig. 2). PEX13 levels were similar in WT cells
and in cells from PBD patients with inactivating mutations
in the 
 
PEX1
 
 (PBD009; Reuber et al., 1997; Collins and
Gould, 1999), 
 
PEX12
 
 (PBD097; Chang et al., 1997), 
 
PEX6
 
(PBD106; Yahraus et al., 1996), 
 
PEX10
 
 (PBD100; Warren
et al., 1998), and 
 
PEX2
 
 (PBD094; Shimozawa et al., 1992)
genes, consistent with the presence of numerous PMP-
containing peroxisomes in these cells (Chang et al., 1999a).
In contrast, PEX13 could not be detected in cells with in-
activating mutations in 
 
PEX16
 
 (PBD061; Honsho et al.,
1998; South and Gould, 1999) or in the CG12 cell line,
PBD400. 
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While many PMPs appear to be degraded in human cells
that lack detectable peroxisomes, some PMPs are stable.
For example, PEX14 levels are similar in 
 
PEX16
 
-deficient
human fibroblasts and fibroblasts from normal individuals
(South and Gould, 1999). PEX14 levels were also normal
in PBD400 and PBD401 cells (data not shown). However,
the PEX14 in these cells is not located in peroxisome-like
structures, but rather is found in the mitochondria (Fig. 3).
A mitochondrial distribution was also observed for over-
expressed versions of the integral PMPs,
 
 
 
PEX13 and
 
ALDP (Fig. 4), as well as PEX12 and PMP34 (data not
shown). A similar mislocalization of PMPs to the mito-
chondria has been reported in 
 
PEX19
 
-deficient cells (Sack-
steder et al., 2000) and observed in 
 
PEX16
 
-deficient cells
(data not shown).
 
Peroxisome Synthesis in the Absence of
Preexisting Peroxisomes
 
To identify the gene defective in PBD400 and PBD401
Figure 1. CG12 cell lines lack detectable peroxisomes. Normal human fibroblasts (left column), PBD400 fibroblasts (middle column)
and PBD401 fibroblasts (right column) processed for indirect immunofluorescence using antibodies specific for catalase (A–C), PMP70
(D–F), PEX13 (G–I), and PEX11b (J–L). Bar, 10 mm.
Figure 2. PEX13 levels are
dramatically reduced in
PBD400 cells. Equal amounts
of total cellular protein ex-
tracts from normal human fi-
broblasts and representatives
of PBD patients with Zell-
weger syndrome from various complementation groups separated by SDS-PAGE and blotted with antibodies specific for PEX13. The
different PBD patients analyzed are: the PEX1-deficient CG1 cell line, PBD009; the PEX12-deficient CG3 cell line, PBD097; the
PEX6-deficient CG4 cell line, PBD106; the PEX10-deficient CG7 cell line, PBD100; the CG8 cell line, PBD109 (the genetic defect has
not yet been identified); the PEX16-deficient CG9 cell line, PBD061; the PEX2-deficient CG10 cell line, PBD094; and the CG12 cell
line, PBD400. 
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cells, we expressed all known human 
 
PEX
 
 genes in these
cells and then assayed the transfected cell populations by
immunofluorescence microscopy using antibodies specific
for peroxisomal membrane and matrix proteins. A mam-
malian plasmid designed to express the 
 
PEX3
 
 cDNA,
pcDNA3-
 
PEX3
 
, was found to restore peroxisome biogen-
esis in both PBD400 and PBD401 cells (Fig. 5). This is
shown here by immunofluorescence experiments in which
PBD400 and PBD401 cells were transfected with either
pcDNA3 or pcDNA3-PEX3, grown for three days, and
then processed for immunofluorescence using antibodies
specific for PMP70, as well as for both PEX14 and the ma-
trix protein marker catalase. Not only do PMP70-contain-
ing vesicles reappear, but PEX14 is now detected in perox-
isomes that also contain catalase. The putative human
PEX3 gene previously was identified based on the se-
quence similarity of its product to that of fungal PEX3
proteins (Kammerer et al., 1998; Soukupova et al., 1999),
all of which play an essential role in peroxisome biogenesis
(Höhfeld et al., 1991; Baerends et al., 1996; Wiemer et al.,
1996).
PBD400 and PBD401 Have Inactivating Mutations
in PEX3
Extragenic suppression and extragenic noncomplementa-
tion have been observed within the PBDs (Geisbrecht et
al., 1998; Chang et al., 1999b). Therefore, it was necessary
Figure 3. PEX14 is mislo-
calized to mitochondria in
PBD400 and PBD401 cells.
Normal human fibroblasts
(A–D), PBD400 (E and F),
or PBD401 (G and H) were
processed for indirect immu-
nofluorescence with antibod-
ies to PEX14 (left column),
PMP70 (B), or stained with
the mitochondrial marker
MitoTracker (D, F, and H).
Note the colocalization of
PEX14 with the peroxisomal
marker PMP70 in normal
cells and the colocalization of
PEX14 with MitoTracker in
PBD400 and PBD401 cells.
Bar, 10 mm.The Journal of Cell Biology, Volume 149, 2000 1350
to examine the PEX3 gene structure from PBD400 and
PBD401 to determine if they actually had mutations in
the PEX3 gene. We first examined the sequence of PEX3
cDNAs from these patients. Total RNA was extracted
from PBD400, PBD401, and control fibroblasts, PEX3
cDNA was synthesized by RT-PCR, and the sequence of
the PCR products was determined directly. These studies
revealed the presence of mutations in the PEX3 cDNA
from both patients, but not from the control individual
(data not shown). The PEX3 cDNA from PBD400 had a
single nucleotide insertion following nt 542 of the ORF,
c.542insT, which shifts the reading frame and terminates
translation after ten out-of-frame codons. The PEX3
cDNA from PBD401 had a nonsense mutation at codon
53, R53ter.
There was no evidence for the WT sequence in PEX3
cDNAs from either PBD400 or PBD401. This indicates
that these patients may be homozygous for the c.542insT
and R53ter mutations, respectively. However, many muta-
tions can dramatically reduce the steady-state abundance
of mRNAs (Maquat, 1995), and we therefore sequenced
the mutated regions of the PEX3 gene from these individ-
uals. Total genomic DNA was extracted from control,
PBD400, and PBD401 fibroblasts, and the regions sur-
rounding each mutation were amplified by PCR using
primers based on the genomic sequence of this gene (Gen-
Bank/EMBL/DDBJ accession number AL031320). Each
PCR product was then sequenced directly. No mutations
were detected in the control genomic DNA, and only the
mutant alleles were detected in each patient (Fig. 6, A and
B). These results suggest that PBD400 and PBD401 are
homozygous for their respective mutations, a result that is
consistent with their consanguineous origins.
The predicted products of the PEX3 alleles in PBD400
and PBD401 would lack approximately the COOH-termi-
nal 3/7 and 6/7 of the protein, respectively. Such severe
frameshift and nonsense mutations are expected to com-
pletely eliminate gene activity. To actually test the effects
of these mutations on PEX3 activity, each mutation was
engineered into the PEX3 expression vector, pcDNA3-
PEX3. The resulting plasmids, pcDNA3-PEX3/c.542insT
and pcDNA3-PEX3/R53ter, were transfected into PBD
400 and PBD401 cells and assayed three days later for
their ability to restore peroxisome biogenesis with pc
DNA3 and pcDNA3-PEX3 as controls. None of the cells
transfected with either of the mutated PEX3 expression
vectors displayed any PEX3 activity (Fig. 6, C and D), as
well as the vector only control (data not shown). In con-
trast, the PEX3 expression vector efficiently rescued per-
oxisome biogenesis in a matched population of patient
cells (data not shown). These results demonstrate that the
PEX3 mutations in PBD400 and PBD401 abrogate PEX3
gene function.
We next assessed the kinetics of PEX3-mediated rescue
of PBD400 cells. PEX3-deficient PBD400 cells were trans-
fected with pcDNA3-PEX3 and processed for indirect
immunofluorescence at various times. No evidence of phe-
notypic rescue could be observed at 4, 8, or 12 h after in-
troducing these plasmids. The earliest time point at which
we could detect PMP70-containing vesicles in any cells of
the transfected population was at 24–28 h after trans-
fection, and this was only in a limited number of the
transfected cells (data not shown). The proportion of
transfected cells containing recognizable peroxisomes was
greater by 48 h after transfection, but was not maximal
until 72 h after transfection. As reported previously for
PEX16- and PEX19-mediated synthesis of peroxisomes in
mammalian cells (Matsuzono et al., 1999; South and Gould,
Figure 4. PBD400 cells mislocalize PEX13myc and ALDPmyc to mitochondria. Vectors designed to express PEX13myc (A–C) or
ALDPmyc (D–F) were transfected into normal human fibroblasts (A and D) or PBD400 cells (B, C, E, and F), and visualized with an-
tibodies to the myc epitope. PEX13myc and ALDPmyc showed a peroxisomal distribution in normal cells (A and D). In contrast,
PBD400 cells mislocalized PEX13myc (B) and ALDPmyc (E) to mitochondria, shown here by their colocalization with the mitochon-
drial marker MitoTracker (C and F). Bar, 10 mm.South et al. Peroxisome Synthesis Is Independent of ER Export 1351
1999), the reconstitution of peroxisome biogenesis in per-
oxisome-deficient cells proceeds in a stepwise fashion,
with PMP-containing vesicles detected first, followed by
the import of peroxisomal matrix proteins. We also ob-
served evidence for this during PEX3-mediated rescue of
peroxisome biogenesis in PBD400 cells (data not shown).
PEX3 Encodes a Peroxisomal Protein
Previous studies have examined the subcellular distribu-
tion of yeast PEX3 and found that it is an integral PMP
(Höhfeld et al., 1991; Baerends et al., 1996; Wiemer et al.,
1996). A similar subcellular distribution has been sug-
gested for the human protein, based on experiments with
tagged versions of PEX3 (Kammerer et al., 1998; Souku-
pova et al., 1999). We used subcellular fractionation exper-
iments to test whether endogenously expressed mamma-
lian PEX3 displayed a similar subcellular distribution. A
postnuclear supernatant was generated from HepG2 cells
and separated by Nycodenz gradient centrifugation. Equal
amounts of each fraction were then assayed for peroxiso-
mal, mitochondrial, and microsomal markers, as well as
for PEX3 by immunoblot (Fig. 7). PEX3 was detected ex-
clusively in the peroxisomal fractions, confirming the pre-
vious localization of this protein to peroxisomes.
PEX3 Transport to Peroxisomes Is Rapid and 
Independent of COPI and COPII
The critical role of PEX3 in human peroxisome membrane
Figure 5. PEX3 expression
restores peroxisome synthe-
sis in CG12 cells. PBD400
cells (A–D) and PBD401
cells (E–H) were transfected
with either pcDNA3 (A and
E) or pcDNA3-PEX3 (B–D
and F–H) and processed after
3 d for indirect immunofluo-
rescence with antibodies spe-
cific for PMP70 (A, B, E, and
F) or for double indirect im-
munofluorescence with anti-
bodies specific for PEX14 (C
and G) and catalase (D and
H). Note the punctate stain-
ing pattern of PMP70 and the
colocalization of PEX14 and
catalase in PEX3-expressing
CG12 cells. Bar, 10 mm.The Journal of Cell Biology, Volume 149, 2000 1352
biogenesis mirrors its function in yeast, where it is also es-
sential for peroxisome membrane biogenesis (Höhfeld et
al., 1991; Baerends et al., 1996; Wiemer et al., 1996). Stud-
ies in the yeast Hansenula polymorpha revealed that cer-
tain PEX3 fusion proteins accumulate in the ER (Baer-
ends et al., 1996), and studies in mammalian cells have
reported that PEX3 overexpression leads to dysmorpho-
genesis of the ER (Kammerer et al., 1998). These data
have led to speculation that PEX3 may transit through the
ER before import into peroxisomes (Kunau and Erd-
mann, 1998). Therefore, we examined the distribution of
human PEX3 at various times after its synthesis. A plas-
mid designed to express a COOH-terminally myc-tagged
form of PEX3, pcDNA3-PEX3myc, was generated and
tested for PEX3 activity. The pcDNA3-PEX3myc plasmid
rescued peroxisome biogenesis in PBD400 cells as effi-
ciently as the WT expression vector, demonstrating
that  the addition of the myc tag had no effect on PEX3
function (data not shown). We then microinjected the
pcDNA3-PEX3myc expression vector into normal human
fibroblasts and followed its expression and subcellular dis-
tribution. At 15 or 30 min after DNA microinjection, we
were unable to see expression of PEX3myc in either the
cytosol, the ER, or peroxisomes. However, by 1 h after in-
jection, PEX3myc staining was readily detected in the per-
oxisomes of microinjected cells (Fig. 8, A and B). Further-
more, PEX3myc was detected only in peroxisomes at this
and all subsequent time points, regardless of whether a cell
was expressing low, moderate, or high levels of PEX3myc.
We also costained cells expressing PEX3myc at the 1 h
time point with antibodies to the ER resident protein, BiP.
However, in no cell did we detect any colocalization of
PEX3myc and BiP (data not shown).
Additional evidence that PEX3 may transit through the
ER en route to the peroxisome comes from a study in the
yeast H. polymorpha in which brefeldin A (BFA), an in-
hibitor of COPI coat formation, caused the accumulation
of PEX3 in the ER and the inhibition of peroxisome bio-
genesis in general (Solomons et al., 1997). Therefore, we
tested whether BFA affected PEX3 import into peroxi-
somes by incubating normal human fibroblasts in medium
containing either a mock control solution (10 ml/ml metha-
nol) or 10 mg/ml BFA for 30 min and then microinjecting
the PEX3myc expression vector. Mock solution or BFA
was maintained throughout the entire experiment. Con-
trols confirmed that BFA had the appropriate effect on
FITC-C5-ceramide distribution in mock and BFA-treated
cells (Fig. 8, C and D). Furthermore, PEX3myc was de-
tected in PMP70-containing peroxisomes 1 h after micro-
injection in similar numbers of cells in both mock- and
BFA-treated cell populations (Fig. 8, E–H).
The fact that PEX3 import was refractory to BFA indi-
cated that any role for the secretory pathway in the trans-
port of PEX3 to peroxisomes would manifest at a step be-
fore COPI-mediated vesicular transport. COPII mediates
the exit of membrane vesicles from the ER and is regu-
lated by SAR1, a small ER-associated GTPase (Barlowe
et al., 1993, 1994; Kuge et al., 1994; Aridor et al., 1995).
Dominant negative mutants of SAR1 have been useful
in the analysis of COPII-mediated processes, particularly
in mammalian cells (Kuge et al., 1994). To determine
whether COPII-mediated processes are important for the
Figure 6. CG12 cells have
inactivating mutations in
PEX3. Direct sequence
analysis of PEX3 geno-
mic DNA from normal,
PBD400, and PBD401 fibro-
blasts. PBD400 cells have a
single thymidine insertion
following nt 542 of the ORF,
resulting in a premature
stop codon 30 nt down-
stream of the insertion (A).
PBD401 cells have a CGA
to TGA nonsense mutation
at codon 53 (B). The single
peak of the genomic se-
quence at these sites indi-
cates the patients are
homozygous for these muta-
tions. The effects of these
mutations were assayed by
transfection of pcDNA3-
PEX3/c.542insT into PBD
400 cells (C) and pcDNA3-
PEX3/R53ter into PBD401
cells (D). 3 d after transfec-
tion, the cells were pro-
cessed for indirect immuno-
fluorescence with antibodies specific for PMP70. The absence of any punctate staining pattern in these cells was also observed with
antibodies specific for catalase (data not shown). Bar, 10 mm.South et al. Peroxisome Synthesis Is Independent of ER Export 1353
trafficking of PEX3 to peroxisomes, we first cloned and se-
quenced the human SAR1 gene. Human SAR1 is virtually
identical to hamster SAR1, and is highly similar to yeast
SAR1 (Fig. 9). Previous studies have established that sub-
stitution of asparagine for threonine at position 39 of hu-
man SAR1 should prevent guanine nucleotide exchange,
trapping SAR1 in the GDP-bound state, and preventing
COPII-mediated membrane budding from the ER (Kuge
et al., 1994). We engineered this Thr39Asn mutation in the
human SAR1 cDNA (SAR1/T39N) and created a COOH-
terminally tagged version of the SAR1/T39N mutant that
carries the vsvg epitope, generating the mammalian cell
expression vector pcDNA3-SAR1/T39N/vsvg. To deter-
mine whether overexpression of SAR1/T39N/vsvg in-
hibited COPII-mediated export from the ER, we co-
transfected normal cells with either empty vector and
pcDNA3-GALT3xHA or pcDNA3-SAR1/T39N/vsvg and
pcDNA3-GALT3xHA. pcDNA3-GALT3xHA is a plas-
mid that expresses an HA-tagged form of the targeting re-
gion of the resident Golgi enzyme, GALT. This protein
cycles between the Golgi apparatus and ER, and becomes
trapped in the ER when SAR1 function is disrupted (Zaal
et al., 1999). GALT3xHA is targeted to the Golgi appara-
tus in normal human fibroblasts (Fig. 10 A), but accumu-
lates in the ER in cells that express high levels of SAR1/
T39N/vsvg (Fig. 10, B and C). We next repeated the
transfection of normal human cells with pcDNA3-SAR1/
T39N/vsvg, waited one day to allow expression of SAR1/
T39N/vsvg to inhibit COPII, and then microinjected these
cells with pcDNA3-PEX3myc. One hour after injection,
the cells were processed for immunofluorescence using
antibodies specific for PEX3myc and SAR1/T39N/vsvg.
PEX3myc was efficiently transported to peroxisomes even
in cells that express high levels of SAR1/T39N/vsvg (Fig.
10, D and E).
PEX3-mediated Peroxisome Synthesis does Not Require 
COPI or COPII
PEX3 import occurs in less than one hour, whereas PEX3-
mediated peroxisome synthesis requires a minimum of
24–28 h. The kinetic discontinuity between these processes
suggests that the import of PEX3 into preexisting per-
oxisomes may differ mechanistically from the process of
PEX3-mediated peroxisome synthesis. Therefore, we tested
whether this process was sensitive to BFA. PBD400 cells
were incubated in mock solution (10 ml/ml methanol) or in
10  mg/ml BFA for 30 min before transfection with the
pcDNA3-PEX3 expression vector. Cells were kept in
mock solution or BFA-containing media throughout the
experiment, and the culture medium was exchanged with
fresh mock solution or BFA-containing medium every 12 h
until the cells were either stained with FITC-C5-ceramide
to confirm that BFA was effective at inhibiting COPI
function (Fig. 11, A and B), or fixed and processed for im-
munofluorescence. Mock- and BFA-treated cells were
stained for PMP70 and for the peroxisomal matrix protein
catalase. PMP- and matrix protein-containing peroxisomes
were detected in both sets of cells 28 h after transfection,
the earliest time at which rescue of PEX3-deficient cells
can be detected (Fig. 11, C–F). Thus, PEX3-mediated res-
cue of peroxisome biogenesis appears to be independent
of COPI.
We also attempted to test the effects of COPII inhibi-
tion on PEX3-mediated peroxisome biogenesis. Control
experiments confirmed that SAR1/T39N/vsvg expression
was as effective at trapping Golgi enzymes in the ER of
PBD400 cells as it was in normal human fibroblasts (Fig.
12, A–C). The PEX3-deficient cell line, PBD400, was also
cotransfected with the SAR1/T39N/vsvg and PEX3 ex-
pression vectors, incubated for two days, and then pro-
cessed for indirect immunofluorescence using antibodies
specific for the peroxisomal membrane marker, PMP70,
and SAR1/T39N/vsvg (Fig. 12, D and E). Peroxisome
structures were observed in many cells expressing high
levels of the dominant negative SAR1 mutant, indicating
that inhibition of COPII-mediated vesicle exit from the
ER does not block PEX3-mediated peroxisome synthesis.
Discussion
Previous studies in yeast have suggested that PEX3 plays
an essential role in the biogenesis of peroxisome mem-
branes (Höhfeld et al., 1991; Baerends et al., 1996; Wiemer
et al., 1996; Hettema et al., 2000). However, the function
of particular peroxins can vary widely between yeast and
humans, particularly those that participate in membrane
biogenesis (Eitzen et al., 1997; South and Gould, 1999;
Tabak et al., 1999). By demonstrating that two Zellweger
Figure 7. PEX3 encodes a peroxisomal protein. A postnuclear
supernatant of HepG2 cells was fractionated by Nycodenz gradi-
ent centrifugation. Equal proportions of each fraction were as-
sayed for the marker enzymes catalase (a peroxisomal marker),
SDH (a mitochondrial marker), and NCR (a microsomal
marker). Equal proportions of each fraction were also assayed by
immunoblot with antibodies to PEX3. A 42-kD band corre-
sponding to PEX3 was detected exclusively in the peroxisomal
fractions.The Journal of Cell Biology, Volume 149, 2000 1354
syndrome patients who lack detectable peroxisomes have
inactivating mutations in PEX3, we establish that human
PEX3 also plays an essential role in peroxisome mem-
brane biogenesis. Furthermore, we find that reexpression
of PEX3 in PEX3-deficient cells leads to the reformation
of peroxisomes, demonstrating that peroxisomes can be
synthesized in the absence of preexisting peroxisomes.
These results mirror results obtained from studies of
PEX16- and PEX19-deficient human cells (Honsho et al.,
1998; Matsuzono et al., 1999; South and Gould, 1999), as
well as from the analysis of yeast pex3 and pex19 mutants
(Hettema et al., 2000).
The most widely accepted model for peroxisome bio-
genesis involves growth and division, growth by uptake of
proteins from the cytoplasm, followed by division of pre-
existing peroxisomes. The biogenic route for peroxiso-
mal matrix proteins clearly follows this model (Lazarow
and Fujiki, 1985), and studies of two mammalian PMPs,
PMP22 (Fujiki et al., 1984) and PMP70 (Imanaka et al.,
1996), suggest that integral PMPs are also imported di-
rectly from the cytoplasm. If this model is correct, we ex-
pect that integral PMPs in PEX3-deficient cells would be
degraded or mistargeted to other cellular membranes,
given that integral membrane proteins are generally not
soluble. Alternatively, it has been hypothesized that some,
and perhaps many, integral PMPs shuttle through the ER
en route to the peroxisome (Kunau, 1998; Titorenko and
Rachubinski, 1998a; Mullen et al., 1999). If this latter
Figure 8. PEX3 is rapidly
targeted to peroxisomes in a
BFA-independent manner.
Normal human fibroblasts
were microinjected with
pcDNA3-PEX3myc and pro-
cessed within 1 h for double
indirect immunofluorescence
with antibodies to the myc
epitope (A) and PMP70 (B).
Normal human fibroblasts
were treated with either a
mock solution (C, E, and F)
or 10 mg/ml BFA (D, G, and
H) for 30 min and then mi-
croinjected with pcDNA3-
PEX3myc. The cells were
kept in mock or BFA-con-
taining media for 1 h, after
which they were either
stained with the Golgi
marker FITC-C5-ceramide to
stain Golgi membranes (C
and D), or processed for
double indirect immunofluo-
rescence with antibodies to
the myc epitope (E and G)
and PMP70 (F and H). Bar,
10 mm.South et al. Peroxisome Synthesis Is Independent of ER Export 1355
model is correct, we should detect an accumulation of inte-
gral PMPs in the ER. Our analysis of PEX3-deficient cells
revealed that the levels of several integral PMPs were re-
duced in abundance, whereas others were mislocalized to
the mitochondria. These results do not rule out the possi-
bility that some small number of integral PMPs reach the
peroxisome via the ER. However, they do support the hy-
pothesis that many PMPs are imported directly from the
cytoplasm.
The synthesis of peroxisomes in the absence of preexist-
ing peroxisomes raises a number of interesting issues, the
most important being the source of membrane for the
nascent peroxisomes. Prior studies have suggested that
PEX3 may transit through the ER en route to the peroxi-
some (Baerends et al., 1996), and may mediate the forma-
tion of peroxisome membranes from the ER (Baerends et
al., 1996; Solomons et al., 1997; Kammerer et al., 1998;
Kunau, 1998; Titorenko and Rachubinski, 1998a). Some of
the observations that have fueled this hypothesis include
the targeting of PEX3 fusion proteins to the ER (Baer-
ends et al., 1996), the accumulation of PEX3 in the ER of
cells treated with the COPI inhibitor, BFA (Solomons et
al., 1997), the inhibition of peroxisome biogenesis and
PMP import by BFA (Solomons et al., 1997; Mullen et al.,
1999), aberrant ER morphology in cells overexpressing
PEX3 (Kammerer et al., 1998), and the detection of other
PMPs in the ER (Elgersma et al., 1997; Titorenko and Ra-
chubinski, 1998b).
Figure 9. Alignment of human, CHO, and yeast homologues of
SAR1. Identical residues are shaded, and the asterisk identifies
threonine 39. The sequence of HsSAR1 is available from Gen-
Bank/EMBL/DDBJ under accession number AF261717.
Figure 10. PEX3 targeting to peroxisomes is independent of
COPII-mediated ER export. Normal human fibroblasts were
cotransfected with either pcDNA3-GALT3xHA and pcDNA3
(A) or pcDNA3-GALT3xHA and pcDNA3-SAR1/T39N/vsvg (B
and C) and processed 1 d later for indirect immunofluorescence
with antibodies to the HA epitope (A and B) and the vsvg
epitope (C). Note the accumulation of GALT in the ER in cells
expressing the SAR1 mutant. Normal human fibroblasts were
also transfected with pcDNA3-SAR1/T39N/vsvg, incubated for
1 d, and then microinjected with pcDNA3-PEX3myc (D and E).
1 h later, the cells were processed for double indirect immuno-
fluorescence with antibodies to the myc epitope (D) and the
vsvg epitope (E). Note that PEX3 is still targeted to peroxi-
somes, even in cells expressing high level of the SAR1 mutant.
Bar, 10 mm.The Journal of Cell Biology, Volume 149, 2000 1356
If PEX3 does transit through the ER en route to the
peroxisomes, then we should detect PEX3 first in the ER
and only later in the peroxisome. We employed a DNA
microinjection system to assess the kinetics of PEX3 im-
port in normal human fibroblasts. A fully functional myc-
tagged version of PEX3, PEX3myc, was detected in perox-
isomes just one hour after DNA microinjection. It was
never observed in any other subcellular structures before
that time, or at any subsequent time, in any of hundreds of
injected cells that were examined. The technical limita-
tions of these experiments cannot rule out the possibility
that PEX3 might move extremely rapidly through the ER,
precluding our ability to detect any ER-associated PEX3.
However, it has been reported that BFA causes an accu-
mulation of PEX3 in the ER, and inhibits peroxisome bio-
genesis in general (Solomons et al., 1997). These earlier re-
ports predict that BFA-treated cells should accumulate
newly synthesized PEX3 in the ER and be resistant to
PEX3-mediated peroxisome biogenesis. In contrast, con-
centrations of BFA that fully inhibited COPI failed to
inhibit the targeting of PEX3 to peroxisomes in normal
fibroblasts, did not lead to an accumulation of PEX3 in the
ER, and had no effect on PEX3-mediated peroxisome
membrane synthesis in PEX3-deficient cells.
The hypothesis that peroxisome membranes arise di-
rectly from the ER does not necessarily mean that the pro-
cess is dependent upon COPI. Vesicle budding from the
ER occurs in a COPII-dependent process (Kuehn and
Schekman, 1997), and it was formally possible that PEX3
targeting and/or PEX3-mediated peroxisome membrane
synthesis involved this early-acting coat protein complex.
In fact, one model for an ER role in peroxisome biogene-
sis invokes COPII as an essential component (Titorenko
and Rachubinski, 1998a). COPII-dependent vesicle formation
requires SAR1, a small ER-associated GTPase (Barlowe
et al., 1993; Kuge et al., 1994). Dominant negative SAR1
mutants that are defective in guanine nucleotide exchange
and lock the protein in the GDP-bound state prevent vesi-
cle budding from the ER (Kuge et al., 1994). We cloned
the human SAR1 gene and found that overexpression of
an analogous human SAR1 mutant, T39N, inhibited trans-
port of proteins from the ER. However, overexpression of
this SAR1 mutant had no detectable effect on PEX3 tar-
geting to peroxisomes in normal human fibroblasts, and
failed to prevent PEX3-mediated peroxisome membrane
synthesis.
Not all vesicle budding processes in the early secretory
organelles depend upon COPII or COPI. Homotypic
membrane budding and fusion may occur independently
of coat protein complexes (Latterich et al., 1995), and it is
formally possible that peroxisomes may arise by budding
of homotypic vesicles from the ER. This hypothesis is sup-
Figure 11. PEX3-mediated
peroxisome synthesis is inde-
pendent of BFA treatment.
PBD400 cells were treated
with either a mock solution
(A, C, and D) or 10 mg/ml
BFA (B, E, and F) for 30 min
and then transfected with
pcDNA3-PEX3. The cells
were incubated in either
mock or fresh BFA-contain-
ing media for 28 h, after
which they were either
stained with FITC-C5-cer-
amide to stain Golgi mem-
branes (A and B) or pro-
cessed for double indirect
immunofluorescence with an-
tibodies specific for PMP70
(C and E) and catalase (D
and F). Bar, 10 mm.South et al. Peroxisome Synthesis Is Independent of ER Export 1357
ported in part by the detection of COPI components on
peroxisomal membranes (Passreiter et al., 1998). How-
ever, homotypic membranes are competent to fuse, as evi-
dent from the rapid fusion of Golgi membranes with the
ER when COPI coats are removed by treatment with BFA
(Klausner et al., 1992). Therefore, if peroxisomes form by
homotypic budding from the ER, we would expect signifi-
cant mixing of peroxisomal and ER proteins, particularly
after BFA treatment, yet this does not seem to be the case.
Numerous studies have established that peroxisomal pro-
teins are distinct from those found in the ER and are not
subject to ER-specific modifications, such as N-linked gly-
cosylation (Lazarow and Fujiki, 1985). Furthermore, BFA
had no effect on the structural integrity of peroxisomes in
human cells, even after prolonged exposure to the drug,
and had no effect on PEX3 targeting or PEX3-mediated
peroxisome membrane synthesis.
The results presented here fail to support the hypothesis
that peroxisomes arise from the ER, and in fact argue
against homotypic-, COPII-, and COPI-dependent mecha-
nisms of ER-to-peroxisome transport of membranes. The
two-pathway model of peroxisome biogenesis proposed
previously (South and Gould, 1999) can, however, provide
a framework for directing future studies of PEX3 function.
This model suggests that peroxisomes typically arise by
the growth and division of preexisting peroxisomes, with
direct uptake of both matrix and membrane proteins from
the cytoplasm (Lazarow and Fujiki, 1985). This model also
suggests that peroxisomes may form by an independent
pathway from some preperoxisomal vesicle, presumably
another endomembrane of the cell. This process is thought
to involve the formation or conversion of a membranous
structure into a PMP-importing vesicle. This allows the im-
port of PEX11 proteins, which mediate peroxisome divi-
sion (Passreiter et al., 1998; Schrader et al., 1998), as well
as the formation of a matrix protein import apparatus, ma-
trix protein import, and metabolic activity. This second
pathway requires the integral PMPs, PEX3 and PEX16
(South and Gould, 1999), as well as a predominantly cyto-
plasmic, partly peroxisomal PMP-binding protein, PEX19
(Matsuzono et al., 1999; Sacksteder et al., 2000). PEX19
appears to participate primarily in PMP import, either as a
PMP-targeting signal receptor or as a chaperone for newly
synthesized PMPs (Sacksteder et al., 2000). Within the
context of this model, the simplest hypothesis is that PEX3
and PEX16 normally participate in PMP import, but can,
at some low rate, also mediate the formation of nascent
peroxisomes. Alternatively, one or both of these peroxins
Figure 12. PEX3-mediated peroxisome synthesis is independent
of COPII. PDB400 cells were cotransfected with either pcDNA3-
GALT3xHA and pcDNA3 (A) or pcDNA3-GALT3xHA and
pcDNA3-SAR1/T39N/vsvg (B and C), and were then processed
2 d later for indirect immunofluorescence with antibodies to the
HA epitope (A and B) and the vsvg epitope (C). PBD400 cells
were also cotransfected with pcDNA3-SAR1/T39N/vsvg and
pcDNA3-PEX3 (D and E) and processed 2 d later for double in-
direct immunofluorescence with antibodies to PMP70 (D) and
the vsvg epitope (E). Note that in PBD400 cells expressing the
SAR1 mutant, GALT accumulates in the ER, yet PEX3 is still
able to rescue peroxisome synthesis. Bar, 10 mm.The Journal of Cell Biology, Volume 149, 2000 1358
could participate in peroxisome membrane synthesis un-
der all conditions.
In addition to the implications for peroxisome biogene-
sis, our results resolve the molecular basis of disease in
complementation group 12 of the PBDs. PBD400 and
PBD401 both display the severe phenotypes of Zellweger
syndrome, as expected for patients who are unable to com-
partmentalize even a small amount of peroxisomal matrix
enzymes. This study brings the number of known PBD
genes to 11, and brings the number of genes that can cause
the Zellweger spectrum diseases: Zellweger syndrome,
neonatal adrenoleukodystrophy, and infantile Refsum dis-
ease, to ten. The genetic basis of disease has yet to be re-
solved in only one of the known groups of PBD patients,
CG8, though the rapid rate of PBD gene identification
makes it likely that it too will soon be known.
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